attenuated live hepatitis A vaccine

Vaccineexperimental

Clinical trial activity

4 trials · 15 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
1

Earliest trial started Oct 1, 2008 (NCT01865968)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • attenuated live hav vaccine
  • hav vaccine
  • live attenuated hav vaccine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05173324Phase 3Feb 1, 2023Aga Khan University, Baylor University, Coptic Hope Center, Emory University, Government of Swaziland, International Agency for Research on Cancer, Sefako Makgatho Health Sciences University, Stellenbosch University, University of Kwa-Zulu Natal, University of New Mexico, World Health Organization
NCT03525119Phase 3May 16, 2018Takeda
NCT02534935Phase 2Aug 31, 2015Pfizer
NCT01865968Phase 4Oct 1, 2008Peking University, Sinovac Biotech Co., Ltd
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (15)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Aga Khan UniversityAcademic/Hospital1012023
Baylor UniversityAcademic/Hospital1012023
Coptic Hope CenterAcademic/Hospital1012023
Emory UniversityAcademic/Hospital1012023
Government of SwazilandGovernment1012023
International Agency for Research on CancerAcademic/Hospital1112023
Peking UniversityAcademic/Hospital1012008
PfizerFor profit1112015
Sefako Makgatho Health Sciences UniversityAcademic/Hospital1012023
Sinovac Biotech Co., LtdFor profit1112008
Stellenbosch UniversityAcademic/Hospital1012023
TakedaFor profit1112018
University of Kwa-Zulu NatalAcademic/Hospital1012023
University of New MexicoAcademic/Hospital1012023
World Health OrganizationGovernment1012023
15 organizations
Page 1 / 1